New Lancet-Published Study Shows AI-Powered Decision Support Tool Improves Decision Quality and Patient Outcomes

Audio By Carbonatix

BOSTON--(BUSINESS WIRE)--Dec 10, 2025--

A newly published randomized clinical trial in The Lancet’s eClinicalMedicine demonstrates that an AI-enabled “digital twin” decision support tool powered by PhenOM ®, OM1’s foundational AI model, significantly improves treatment decision quality, shared decision-making, and long-term outcomes for patients with knee osteoarthritis (OA).

The tool evaluated in the study—Joint Insights, co-developed by OM1 and Dell Medical School at The University of Texas at Austin—uses PhenOM to generate individualized predictions of surgical benefit, risk, recovery, and quality-of-life changes. The study represents one of the first rigorous randomized trials assessing an AI-enabled decision aid in orthopedics.

Patients who used the PhenOM-powered tool experienced higher decision quality, better medium- and long-term physical function, stronger alignment between treatment choices and personal preferences, and lower decision conflict and regret compared with digital education alone. These results reinforce earlier findings published in JAMA Network Open from a prior clinical trial.

Addressing a Longstanding Challenge in Orthopedic Care

Knee replacement is among the most common orthopedic procedures, yet nearly 20% of patients do not experience meaningful improvement, leading to dissatisfaction and increased costs. Joint Insights addresses this gap by generating AI-driven digital twins, or patient-specific simulations of likely outcomes. These predictions help clinicians set clearer expectations, guide informed conversations, and support patients in choosing the right treatment.

Joint Insights has been part of routine clinical practice at Dell for several years. It is fully integrated into the health system’s electronic medical record and combines patient-reported outcomes, education, personal values, and predictive modeling into a streamlined workflow for patients and providers.

PhenOM: The AI Foundation Behind the Results

Joint Insights is built on PhenOM, OM1’s foundational AI model trained on over one billion patient-years of real-world data, including clinical data from over 700,000 total knee arthroplasty patients. PhenOM uses advanced phenotyping technology to identify patient subtypes and forecast events, treatment response, and disease trajectories across conditions.

The study authors describe the findings as a strong case for adopting AI-enabled decision aids that deliver personalized analytics at the point of care. They also note that digital twin models could extend beyond orthopedics, supporting decisions related to physical therapy, behavioral interventions, lifestyle strategies, and other treatments. PhenOM’s broad applicability enables similar capabilities across multiple therapeutic areas.

Access Joint Insights and PhenOM-Powered Analytics

Individuals and healthcare providers interested in Joint Insights or in applying PhenOM-powered predictive insights across therapeutic areas can visit the OM1 website or contact [email protected] for more information.

About OM1

OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251210966111/en/

CONTACT: Media

Chelsea Phou

Marketing Manager

[email protected]

om1.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MANAGED CARE SOFTWARE RESEARCH GENERAL HEALTH PROFESSIONAL SERVICES DATA MANAGEMENT TECHNOLOGY ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE HEALTH OTHER SCIENCE

SOURCE: OM1

Copyright Business Wire 2025.

PUB: 12/10/2025 09:00 AM/DISC: 12/10/2025 09:00 AM

http://www.businesswire.com/news/home/20251210966111/en